Hedge fund manager J. Kyle Bass slammed US Patent & Trademark Office, after it blocked his attempt to challenge a patent held by drugmaker Biogen. The Patent Trial and Appeal Board, which is part of the USPTO, said on Tuesday that it was denying Bass' petition to review a patent for a multiple sclerosis drug licensed by Biogen.